

REMARKS

Applicant has cancelled claims 1-8 and 11-14, and amended claims 9 and 15. Claims 9, 10 and 15 are currently pending in the application.

The Invention

The present invention provides a treatment for visual field defects associated with the use of GABAergic drugs. The present invention provides novel compositions that consist essentially of a GABAergic drug and vitamin B6.

GABAergic drugs, as defined by the present invention, increase GABA levels in the brain. See paragraphs [0002] and [0016]. It is known that high doses (e.g. 300mg/day) of vitamin B6 can counteract the GABA-increasing effects of GABAergic drugs, such as, for example, vigabatrin (GVG). See Mueller et al.

The amount of vitamin B6 in the claimed composition has been carefully selected so as to treat visual field defects without interfering with the therapeutic benefits of the GABAergic drug.

Amendments to the Claims

By this amendment, claims 9 and 15 have been amended to more clearly define the invention. Claims 9 and 15 now recite that the amount of vitamin B6 administered is about 50mg/day to about 100mg/day.

Respectfully submitted,



Margaret C. Bogosian
Attorney for Applicant
Registration No. 25,324

Date: 2/10/04

Margaret C. Bogosian
Patent Counsel
Brookhaven National Laboratory
Building 475D - P.O. Box 5000
Upton, New York 11973-5000
Telephone: (631) 344-7338